NCT01248481已完成不适用
Combined Use of a Basal Insulin and Glucobay For Reducing PPG to End Diabetes Progress
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- Bayer
- 入组人数
- 539
- 主要终点
- Change in HbA1c
研究概览
简要总结
To evaluate the effectiveness of Glucobay when combined with a basal insulin under daily-life treatment conditions in a large sample of Korean patients.
研究设计
- 研究类型
- Observational
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Signed written informed consent
- •Age ≥ 18 years
- •Diagnosed of type 2 diabetes for at least 6 months prior to enrollment
- •Patients treated with stable dose of a basal insulin (insulin glargine or insulin detemir) at least 2 months
- •HbA1C≥7.5 and ≤10.0%
排除标准
- •Exclusion criteria must be read in conjunction with the local product information
研究组 & 干预措施
Group 1
干预措施: Acarbose (Glucobay, BAYG5421) (Drug)
结局指标
主要结局
Change in HbA1c
时间窗: After 20 weeks
次要结局
- Duration and dose of acarbose treatment(After 20 weeks)
- Postprandial Blood Glucose(After 20 weeks)
研究者
相似试验
已完成
不适用
GlucoVIP - Diabetes Treatment by Glucobay® With a Special Therapeutic View to Chosen Patient GroupsDiabetes MellitusNCT00909051Bayer15,729
已完成
不适用
CGM Evaluation of Glucose Excursions in Basal Insulin Treated T2DM at Fasting Glucose TargetType 2 DiabetesNCT01548222Diabetes Care Center20
已完成
4 期
A Study Comparing Insulin Intensification Therapies in Patients With Type 2 Diabetes MellitusDiabetes Mellitus, Type 2NCT01175811Eli Lilly and Company402
已完成
4 期
Comparison of Two Treatment Regimens in Patients With Type 2 Diabetes After Short-term Intensive Insulin TherapyType 2 Diabetes MellitusNCT03359837Sanofi384
已完成
4 期
Basal Insulin Glycemic ControL With DEglugec vs Aspart Via PumpType1 Diabetes MellitusNCT04409587Mountain Diabetes and Endocrine Center59